Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

NCT00574275 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

546

Enrollment

INDUSTRY

Sponsor class

Stopped Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival

Conditions

Pancreatic Neoplasm

Interventions

DRUG: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
DRUG: Placebo
DRUG: Gemcitabine

Sponsor

Sanofi

Collaborators

[object Object]